EP Patent

EP4218735A2 — Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics

Assigned to Flamel Ireland Ltd · Expires 2023-08-02 · 3y expired

What this patent protects

Modified release formulations of gamma-hydroxybutyrate having improved dissolution and pharmacokinetic properties are provided, and therapeutic uses thereof.

USPTO Abstract

Modified release formulations of gamma-hydroxybutyrate having improved dissolution and pharmacokinetic properties are provided, and therapeutic uses thereof.

Drugs covered by this patent

sodium-oxybate (SODIUM OXYBATE)

Patent Metadata

Patent number: EP4218735A2
Jurisdiction: EP
Classification: —
Expires: 2023-08-02
Drug substance claim: No
Drug product claim: No
Assignee: Flamel Ireland Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.